ERBB2 and colorectal cancer: In colorectal cancer which is the third-most common cancer worldwide, CA produced its anti-cancer effects by inhibiting the neuregulin1 (NRG1)-induced heterodimerization of HER2 and HER3 and their consecutive phosphorylation [118].